US Patent Issued to Seattle Children's Hospital on Dec. 23 for "Defined composition gene modified T-cell products" (Washington Inventor)

ALEXANDRIA, Va., Dec. 23 -- United States Patent no. 12,503,507, issued on Dec. 23, was assigned to Seattle Children's Hospital (Seattle).

"Defined composition gene modified T-cell products" was invented by Michael C. Jensen (Bainbridge Island, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then act...